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Letter to the Editor
Elevated b-hydroxybutyric acid with no
ketoacidosis in type 2 diabetic patients
using sodium-glucose cotransporter-2
inhibitors
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To the Editor,
SGLT2 inhibitor (SGLT2i) class of medications are known
to cause to euglycemic diabetic ketoacidosis (euDKA) as
reported in the article by Lin et al. in your esteemed
publication about this entity being reported for the first
time in Taiwanese population.1 We wish to share the
findings from our center to further expand the spectrum
of findings associated with SGLT2i therapy. SGLT2i treat-
ment in patients with preexisting atherosclerotic heart
disease and those with high risk of cardiovascular events
is associated with a reduction in cardiovascular (CV)
mortality, heart failure hospitalizations, and death from
any cause.2 Although the mechanism of the CV benefit
from SGLT2i is likely to be multifactorial with a low level
of ketonemia being one of the potential mechanisms.3 In
our study population, we measured serum b-hydroxybu-
tyric acid (BHA) to assess the occurrence of asymptomatic
ketogenesis in patients with type 2 diabetes mellitus after
initiation of SGLT2i therapy. Between June 2015 and
March 2016, we measured serum BHA before and after
starting an SGLT2 inhibitor in 28 patients at our outpa-
tient endocrinology and metabolic medicine clinic. BHA
levels >2.8 mg/dL was considered elevated. We also
analyzed changes in serum HbA1c and body mass index
(BMI) before and after starting SGLT2i. Baseline popula-
tion characteristics and results are detailed in Table 1.
In our study, we found 14% (n Z 4) of the patients had
elevated BHA without any acidosis (normal serum bica-
bonate). To the best of our knowledge this very interesting
finding has not been previously reported. Elevation in BHA
levels was not associated with patient’s age, duration of
SGLT2i use, serum creatinine, change in BMI or change in
HbA1c. Interestingly all 4 patients with increased in BHA
levels were male. SGLT2 inhibitors’ proven CV benefits
could be potentially related to asymptomatic low grade
ketonemia.3 SGLT2 inhibition induces a rapid increase in
urinary glucose excretion, the resultant decrease in circu-
lating insulin levels lead to increased lipolysis, which in turn
would increase the rate of ketone body formation in the
liver.4 In addition, patients treated with SGLT2i have higher
circulating glucagon levels. Phlorizin, a nonselective in-
hibitor of the SGLT family transporters has shown to de-
creases urinary excretion of ketone bodies such as BHA.5 In
the absence of metabolic acidosis, these patients were
managed conservatively. Our study provides another point
of education for the treating physicians including endocri-
nologists, emergency physicians and a wider pool of in-
ternists that elevated BHA in patients with SGLT2 therapy
should not be blindly considered as a surrogate marker for
euDKA. Clinical and biochemical correlation with elevated
anion gap and acidosis (indicated by low serum bicarbonate
levels or pH) should be present to label these patients as
euDKA.
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Table 1 General demographics and results.
Total number of patients (n) 28
Males (n) 75% (21)
Mean Age (years) SD 56  6 years
Mean Duration of Diabetes Mellitus 8.26  4.91
Mean Duration of SGLT2 use (days) SD 207  103 days
Mean Creatinine  SD 0.83  0.25 mg/dL 0.5e1.5 mg/dL
Mean Serum Bicarbonate SD 21.7  2.06 mEq/L Normal 20e32 mEq/L
HbA1c
Before SGLT2 use (% SD) 8.2  1.3
After SGLT2 use (% SD) 7.3  0.9 P Z <0.001
BMI
Before SGLT2 use (kg/m2 SD) 35.0  6.1
After SGLT2 use (kg/m2 SD) 33.1  6.0 P Z <0.001
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